Drug Trial Radar · NCT03726658
Zelquistinel in the Treatment of Adults With Major Depressive Disorder
Last checked: Nov 19, 2026Latest source record: Apr 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
226
Actual
Start
Nov 8, 2018
Primary completion
Oct 23, 2019
Study completion Oct 23, 2019
Sponsor
- Lead sponsor
- Syndeio Biosciences, IncIndustry
- Sponsor type
- Industry
- First posted
- Oct 31, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy and safety of AGN-241751 in participants with Major Depressive Disorder
Conditions
- Major Depressive Disorder
Interventions
AGN-241751Drug
AGN-241751 is supplied in tablet form
PlaceboDrug
Placebo is supplied in tablet form
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A: Change in MADRS Score at 1 Day the Initial Dose of AGN-241751 Reported as Change From Baseline in Treated Group Compared With Change From Baseline in Placebo GroupTime frame: Baseline (Day1) to Day 2
- Part B: Change From Baseline in MADRS Score at Day 8 Post the Initial Dose of AGN-241751 (i.e. 1 Day After the Seventh Daily Dose)Time frame: Baseline (Day 1) to Day 8
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
Alea Research
Phoenix, Arizona
Collaborative Neuroscience Network, LLC
Garden Grove, California
Atlanta Center for Medical Research
Atlanta, Georgia
Hassman Research Institute
Berlin, New Jersey
Northwest Clinical Research Center
Bellevue, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.